Reaction
Short Stature reporting signals
As of the last recalculation, Short Stature appears in 258 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 462.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 50 | 462.2 | 464.4 |
| Tofacitinib Citrate | 52 | 400.5 | 402.1 |
| Anakinra | 59 | 371.7 | 373.0 |
| Naproxen Sodium Tablet, Coated | 34 | 233.2 | 233.7 |
| Naproxen Sodium, Coated Tablets | 34 | 233.2 | 233.7 |
| Naproxen Sodium 220Mg | 34 | 232.8 | 233.4 |
| Busulfan | 34 | 200.6 | 201.1 |
| Adalimumab-Fkjp | 69 | 163.7 | 163.9 |
| Adalimumab-Aaty | 69 | 160.2 | 160.4 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 38 | 153.4 | 153.6 |
| Adalimumab-Adaz | 70 | 146.5 | 146.7 |
| Human Immunoglobulin G | 31 | 137.6 | 137.8 |
| Triamcinolone Acetonide | 38 | 116.2 | 116.3 |
| Tocilizumab | 96 | 107.5 | 107.6 |
| Brinzolamide | 7 | 66.8 | 66.9 |
| Fludarabine Phosphate | 28 | 64.3 | 64.4 |
| Thiotepa | 7 | 60.8 | 60.8 |
| Asfotase Alfa | 6 | 49.4 | 49.5 |
| Timolol | 7 | 48.0 | 48.0 |
| Tofacitinib | 73 | 44.1 | 44.1 |
| Brimonidine Tartrate | 8 | 37.4 | 37.4 |